Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase Ib Trial of Enzalutamide in Combination With Radiation Therapy and LHRH Agonist Therapy in the Management of Intermediate and High-Risk Prostate Cancer

NCT02023463 is registered in ClinicalTrials.gov with Thomas Jefferson University as lead sponsor.

NCT NCT02023463
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02023463 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase Ib Trial of Enzalutamide in Combination With Radiation Therapy and LHRH Agonist Therapy in the Management of Intermediate and High-Risk Prostate Cancer
Lead sponsor
Thomas Jefferson University
Phase
Phase 1
Overall status
Active, not recruiting
Start date
April 2, 2014
Completion date
January 1, 2040
Enrollment
25 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

adenocarcinoma of the prostate, recurrent prostate cancer, stage iib prostate cancer, stage iii prostate cancer, stage iv prostate cancer